Fail Safe Cell Therapy

1-888-613-6862
info@pancella.com

Tag Archives: FailSafe

MilliporeSigma Licenses CRISPR Genome-Editing Technology to PanCELLa

  • Licenses aim to accelerate drug discovery leading to development of new therapies
  • PanCELLa agreement marks MilliporeSigma’s first CRISPR license for bioproduction

“MilliporeSigma’s latest CRISPR licenses are the impetus for drug discovery that promises to accelerate research leading to the development of new therapies,” said Chris Ross, interim CEO, MilliporeSigma. “We have been at the forefront of gene-editing innovation for 16 years and continue to work, both ethically and responsibly, with the global scientific community to solve problems by using our patented CRISPR technology.”….
to read the full article, please click here

Making Unsafe Safe with panCELLa’s Universal Stem Cells

The inventors of panCELLa’s exclusive induced Allogeneic Cell Tolerance have recently published a letter in CellStemCell.  This letter is in response to Bryan J. González, et. all’s “How Safe Are Universal Pluripotent Stem Cells?”  Dr. Andras Nagy, panCELLa’s scientific founder and Chair of our Scientific Advisory Board, refers to this opinion piece as “proof of… Continue Reading

panCELLA receives research and development support for cell therapy

panCELLa is pleased to announce that it will receive advisory services and up to $400,000 from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) to help further research and development of its technology platforms for cell therapy. Support from NRC IRAP will go toward the research and development of a two-step… Continue Reading

EVOTEC EXPANDS ITS IPSC-BASED CELL THERAPY PLATFORM EVOCELLS THROUGH LICENSING AGREEMENT WITH PANCELLA

“We welcome the partnership with Evotec. Evotec’s widely recognised expertise and existing portfolio of iPSC-related technology platforms will allow panCELLa to rapidly advance its own therapeutic interests in NK cell therapy, pancreatic islet production and iPSC-derived MSC platform, in addition to enabling panCELLa to make its platform technologies widely available. I believe that the investment by Evotec in our company is a strong validation of the leading role of panCELLa in the field of regenerative medicine and in the utility of its platform technologies. We welcome Dr Andreas Scheel to our Board.” Continue Reading

Cartherics and panCELLa announce collaborative agreement to develop pluripotent cell lines for cell therapy

Cartherics Pty Ltd (“Cartherics”) and panCELLa Inc. (“panCELLa”) are pleased to announce their collaboration to research, develop and commercialize products for the treatment of cancer and other debilitating diseases using cell therapy.  panCELLa will integrate their exclusive FailSafeTM technology into Cartherics’ proprietary homozygous HLA haplotype cells to bring the power of safe cell therapy to… Continue Reading